All News

How I do it, treatment of CGA with Dr. @philseo, who thoughtfully paused so everyone could take a picture of this slide knowing full well it was already at our fingertips! Such a gentleman! #RNL2024 @RheumNow https://t.co/8kqacqkRM6

https://twitter.com/uptoTate/status/1751615517301895508/photo/1

Dr. Phillip Seo contemplates if Taylor and Travis had vasculitis, surely the dose for each would not be the same. Wish you were here @rheum_cat to weigh in on this. #RNL2024 @rheumnow https://t.co/1ynctgIknx

https://twitter.com/KDAO2011/status/1751614668861305117/photo/1

Dr @anisha_dua's takehome points for treating GPA in 2024 *RTX and CYC are both effective followed by RTX at least 500mg q 6 mo for at least 2 years *PLEX not generally used, but may be effective in preventing ESKD *Rapid GC tapering may not be suitable for all pts *Avacopan is… https://t.co/haI19Sgpmu https://t.co/jhjXLwd0Uw

PJP prophylaxis in GPA. Always a trade off but these things are not created equal. PJP or sepsis are much worse on average than the AEs @anisha_dua @RheumNow #RNL2024 https://t.co/9sECd7fSRk

https://twitter.com/RichardPAConway/status/1751613348032962607/photo/1

Remission maintenance in AAV. First 2 years is clear - fixed dose RTX is superior. After that it is clear that following ANCA is suboptimal, could consider either B-cell return dosing or ongoing fixed dosing @anisha_dua @RheumNow #RNL2024 https://t.co/0Elir88L9U

https://twitter.com/RichardPAConway/status/1751613096366326061/photo/1

Maintenance issues in GPA. Clear messages. 1. RTX is best 2. Fixed 6-monthly RTX best for 1st 2 years. 3. Don't stop RTX at 2 years! @anisha_dua @RheumNow #RNL2024 https://t.co/jS3jWm0CcS

https://twitter.com/RichardPAConway/status/1751612592920137951/photo/1

The answer to "always" is "always" no, correct? PEXIVAS low dose is a great baseline plan, but always adjust in light of the individual patient both upfront and especially if things aren't working out @anisha_dua @RheumNow #RNL2024 https://t.co/RPnpAdB1eG

https://twitter.com/RichardPAConway/status/1751610831576698888/photo/1

Rapid GC taper in ANCA vasculitis #RNL2024 @RheumNow @anisha_dua PEXIVAS - reduced GC is safe, decreased ifns Retrospective real world - 234 pts. Reduced dose GC+RTX increased death/ESKD HR 2.42. No difference in infections https://t.co/SWIUSyVbWb

https://twitter.com/ericdeinmd/status/1751610127252148272/photo/1

Great talk @anisha_dua re:AAV, solid updates on mgmt decisions Looking forward to debating this study with @lastwalsh w/@MatsJunek moderating... @TerrierBen any updates on when your RWD study will be published? @RheumNow https://t.co/ywVaOIp2WJ

https://twitter.com/EBRheum/status/1751609973082124761/photo/1

Contrasing ACR/VF and EULAR GPA guidelines from @anisha_dua @RheumNow #RNL2024 https://t.co/RLJx9fJHGk

https://twitter.com/RichardPAConway/status/1751609824973139984/photo/1

"Real world studies: When people stop being polite and start getting real." Dr @anisha_dua #RNL2024 Comparing Walsh to Nagle in terms of primary outcomes, regimens, pt populations, and plasma exchange. @RheumNow https://t.co/io8OGnWxdS

https://twitter.com/uptoTate/status/1751609810573832670/photo/1

Is there data for PLEX in GPA? @anisha_dua #RNL2024 @RheumNow PEXIVAS negative study But subgroups show decreased dialysis... But, no improvement in mortality and increased infection risk https://t.co/K9VbcNNsge

https://twitter.com/ericdeinmd/status/1751608903714926770/photo/1

#RNL2024 @RheumNow @anisha_dua Throwing the kitchen sink in severe GPA CYC + RTX combo - sick population (median GFR 9, 47% on HD, 52% DAH, all received PLEX too) - 85% survival, 69% not ESKD, low rates of relapse (13% at 36 mos) But, prolonged B cell depletion, aggressive Rx https://t.co/9AZFMQ3o9P

https://twitter.com/ericdeinmd/status/1751608396627718341/photo/1

@anisha_dua reviews differences between EULAR vs ACR Vasculitis guidelines #RNL2024 @RheumNow https://t.co/1aIbnX5KBI

https://twitter.com/KDAO2011/status/1751607655934709827/photo/1

@anisha_dua reviews GPA management in 2024. Here are your ACR/VF 2021 and EULAR 2022 guideline updates. Review these regimen options for your patients. #RNL2024 @RheumNow https://t.co/SvQoe0YKKV

https://twitter.com/uptoTate/status/1751607745214587184/photo/1

Clinical Pearl! @DrCassySims currently treats with ASA 81mg po daily during vasculitis pregnancies at 12 weeks for preeclampsia ppx. She notes there is some data/use of 162mg po daily in Europe which may change the way we practice in the future. #RNL2024 @RheumNow

Pregnancy in vasculitis checklist: - goals and timeline - disease activity in 12 mos - is there end organ damage? - Review Rx - h/o clots/miscarriages, APLS? - Check Ro/La - Role for ASA? - Refer to MFM Catherine Sims #RNL2024 @RheumNow

How do vasculitis pts do during pregnancy? Variable due to different diagnoses of flares Gatto 2012: TA 3% flare, GPA 45% flare Fredi 2015: 35% flare Nguyen 2021: LVV 25% flare, 36% SVV -Catherine Sims #RNL2024 @RheumNow

You can still attend RheumNow Live! Below is a preview of one of our "STEP" talks - by Mike Putman, MD, who brings his vast knowledge to the forefront, shedding light on Myths & Mistakes on ANCA-Associated Vasculitis. https://t.co/LzcVytLDij Register: https://t.co/NWXKNhQzc5 https://t.co/ogAfTtH5Nk

IL-17 pathway as a target in giant cell arteritis - full read review of pathogenic role of IL-17 and Th17 cells, in #GCA; backed up by the phase II proof-of-principle TiTAIN study showing potential efficacy of secukinumab in GCA pts https://t.co/MThzw2joGO https://t.co/PmrJjf9C3a

The IL-17 pathway as a target in giant cell arteritis

Topics

All News

Do you get our email newsletter?